LENZ Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.74) Per Share (NASDAQ:LENZ)

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Equities researchers at William Blair issued their Q1 2024 EPS estimates for shares of LENZ Therapeutics in a research note issued to investors on Monday, April 15th. William Blair analyst T. Lugo forecasts that the company will earn ($0.74) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for LENZ Therapeutics’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at ($0.46) EPS, Q4 2024 earnings at ($0.44) EPS, FY2024 earnings at ($2.10) EPS and FY2025 earnings at ($2.95) EPS.

Several other brokerages have also weighed in on LENZ. Leerink Partnrs reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research report on Monday. SVB Leerink assumed coverage on shares of LENZ Therapeutics in a research report on Monday. They issued an “outperform” rating and a $32.00 price objective on the stock. Citigroup assumed coverage on shares of LENZ Therapeutics in a research report on Wednesday, April 10th. They issued a “buy” rating and a $34.00 target price for the company. Finally, Piper Sandler initiated coverage on LENZ Therapeutics in a research report on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price objective for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.33.

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock opened at $17.49 on Wednesday. LENZ Therapeutics has a twelve month low of $14.07 and a twelve month high of $29.82. The company has a market cap of $145.52 million, a PE ratio of -1.12 and a beta of 0.20.

Insider Activity at LENZ Therapeutics

In related news, Director Ra Capital Management, L.P. acquired 998,009 shares of the stock in a transaction that occurred on Thursday, March 21st. The shares were acquired at an average price of $15.03 per share, for a total transaction of $15,000,075.27. Following the completion of the purchase, the director now directly owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 38.40% of the stock is currently owned by insiders.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.